CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current Assets:
Cash and cash equivalents	$ 110,845	$ 123,794
Accounts receivable, net of reserves of $4,266 in 2019 and $4,702 in 2018	286,154	248,855
Inventories	196,876	173,303
Other current assets	118,423	108,220
Total current assets	712,298	654,172
Long-Term Assets:
Property and equipment, net	469,982	437,270
Operating lease right-of-use assets (Notes 2 and 7)	81,555	0
Goodwill	215,157	214,489
Intangible assets, net	37,989	41,825
Other long-term assets	207,256	189,593
Total long-term assets	1,011,939	883,177
TOTAL ASSETS	1,724,237	1,537,349
Current Liabilities:
Accounts payable	67,606	69,534
Accrued liabilities	256,329	260,683
Line of credit	251,528	398,937
Current portion of deferred revenue	43,446	41,290
Total current liabilities	618,909	770,444
Long-Term Liabilities:
Deferred income tax liabilities	32,415	29,267
Long-term debt	700,552	601,348
Long-term deferred revenue, net of current portion	52,129	60,697
Long-term operating lease liabilities (Notes 2 and 7)	69,331	0
Other long-term liabilities	79,352	84,826
Total long-term liabilities	933,779	776,138
Total liabilities	1,552,688	1,546,582
Commitments and Contingencies (Note 15)
Stockholders’ Equity (Deficit):
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 105,478 shares in 2019 and 105,087 shares in 2018; Outstanding: 86,103 shares in 2019 and 86,100 shares in 2018	10,548	10,509
Additional paid-in capital	1,170,962	1,138,216
Deferred stock units: Outstanding: 144 units in 2019 and 162 units in 2018	4,381	4,524
Retained earnings	1,396,315	1,167,928
Accumulated other comprehensive loss	(40,583)	(41,791)
Treasury stock, at cost: 19,375 shares in 2019 and 18,988 shares in 2018	(2,370,377)	(2,288,899)
Total IDEXX Laboratories, Inc. stockholders’ equity (deficit)	171,246	(9,513)
Noncontrolling interest	303	280
Total stockholders’ equity (deficit)	171,549	(9,233)
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)	$ 1,724,237	$ 1,537,349